Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.76%86 ROA % is 44.98% as of Mar. 2026, which is 216% above its 10-year median of 14.23. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Procter & Gamble Health ranks better than 98.71% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Procter & Gamble Health's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹3,784 Mil.
Procter & Gamble Health's average Total Assets over the quarter that ended in Mar. 2026 was ₹8,414 Mil. Therefore, Procter & Gamble Health's annualized ROA % for the quarter that ended in Mar. 2026 was 44.98%.
The historical rank and industry rank for Procter & Gamble Health's ROA % or its related term are showing as below:
BOM:500126'
s ROA % Range Over the Past 10 Years
Min: 6.37 Med: 14.23 Max: 60.98
Current: 37.67
During the past 13 years, Procter & Gamble Health's highest ROA % was 60.98%. The lowest was 6.37%. And the median was 14.23%.
BOM:500126's ROA % is ranked better than 98.71% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.76
vs BOM:500126: 37.67
Procter & Gamble Health (BOM:500126) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's ROA % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Procter & Gamble Health (BOM:500126) has a ROA % of 44.98% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Procter & Gamble Health and its competitors. This is 216% above median its historical median of 14.23. Over the past decade, Procter & Gamble Health's ROA % has ranged from 6.37 to 60.98. According to the industry distribution chart, Procter & Gamble Health ranks #13 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Procter & Gamble Health's ROA % too high?
Procter & Gamble Health's current ROA % of 44.98% is 216% above median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 6.37 to a high of 60.98. The Drug Manufacturers industry median ROA % is 2.76. Procter & Gamble Health's value of 44.98% is 1529.7% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #13 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #13 out of 1008 companies for ROA %. This places Procter & Gamble Health in the top 1% of its industry — outperforming the majority of peers. The industry median ROA % is 2.76. Procter & Gamble Health's value of 44.98% is 1529.7% above this benchmark. Historically, Procter & Gamble Health's own ROA % has ranged from 6.37 to 60.98 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 2.76, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.76, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current ROA % of 44.98% is 1529.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current ROA % is 44.98%, which is 216% above median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current ROA % is 44.98%, which is 216% above median its 10-year median of 14.23 and 1529.7% above the Drug Manufacturers industry median of 2.76. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current ROA % is 44.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
ROA %: 44.98% (216% above median its 10-year median of 14.23)
GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
Industry Position: 1529.7% above the Drug Manufacturers median (#13 of 1008)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
